Indeed, one pharmacy (unrelated to BPC specifically) was hit with FDA warnings for sterility problems in its peptide injectable products
Results demonstrated that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, the peptide produced no clinically significant alterations in IGF-1 levels, no glucose intolerance or insulin resistance, and no anti-AOD9604 antibodies in any participant
BPC-157s human trials were early-phase IBD
non-diabetic populations, and is attributed to differences in baseline insulin resistance, beta cell function, and GLP-1 receptor sensitivity
Tesamorelin works by stimulating the pituitary gland to release growth hormone
See what changes the dose above for the detail